Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~* Documented progression from most recent line of therapy~* 1-3 prior lines of therapy~* Measurable disease~* Life expectancy ≥3 months~* Prior treatment with Lenalidomide permitted if:~  1. Best response achieved was ≥Partial Response (PR)~ 2. Patient was not refractory~ 3. Patient did not discontinue due to a Grade ≥3 related adverse event~ 4. Subject did not receive more than 9 cycles of Lenalidomide and had at least 9 months between the last dose of Lenalidomide and progression~Exclusion Criteria:~* Subjects with non-secretory or oligo-secretory or serum free light-chain only myeloma~* Active plasma cell leukemia~* Known Human immunodeficiency virus (HIV) infection or active hepatitis A, B, or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide + Dexamethasone (Type: ACTIVE_COMPARATOR): None
- Lenalidomide + Dexamethasone +Elotuzumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).